Response to efavirenz-containing regimens in previously antiretroviral-naive HIV-positive patients: The role of gender

Journal of Acquired Immune Deficiency Syndromes

Volumn 46, Issue 1, 2007, Pages 62-67

  Smith, Colette J ^a   Sabin, Caroline A ^a   Youle, Mike S ^b   Lampe, Fiona C ^a   Bhagani, Sanjay ^b   Madge, Sara ^b   Puradiredja, Dewi ^a   Johnson, Margaret A ^b   Phillips, Andrew N ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Antiretroviral therapy; Efavirenz; Gender

Indexed keywords

ABACAVIR; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG ERUPTION; DRUG WITHDRAWAL; ETHNICITY; FEMALE; HETEROSEXUALITY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK; SURVIVAL; TREATMENT FAILURE; TREATMENT RESPONSE; UNITED KINGDOM; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; MALE; SEX CHARACTERISTICS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 34848868797     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31813e5e20     Document Type: Article

References (35)

1. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22-29.
2. Martin JV, Soriano V, Jimenez-Nacher I, et al. Overall trends in CD4 counts and plasma viremia in an urban clinic since the introduction of highly active antiretroviral therapy. Clin Microbiol Infect. 2001;7:678-681.
3. Gazzard B, for the BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 2005;6:1-61.
4. Health Protection Agency (HIV/STI Department CDSC). HIV New Diagnoses Quarterly Surveillance Tables. UK Data received to the end of March 2007. Available at: http://www.hpa.org.uk/infections/topics_az/hiv_and_sti/hiv/ epidemiology/files/Quarterlies%202007/2007_Q1_(Mar)_HIV_Quarterlies.pdf. Accessed July 10, 2007.
5. Spire B, Carrieri P, Garzot MA, et al. Factors associated with efavirenz discontinuation in a large community-based sample of patients. AIDS Care. 2004;16:558-564.
6. Nicastri E, Angeletti C, Palmisano L, et al. Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS. 2005;19:577-583.
7. Moore A, Mocroft A, Madge S, et al. Gender differences in virologic response to treatment in an HIV-positive population: a cohort study. J Acquir Immune Defic Syndr. 2001;26:159-163.
8. Sabin CA, Lampe F, Chaloner C, et al. An audit of antiretroviral treatment use in HIV-infected patients in a London clinic. HIV Med. 2003;4:87-93.
9. d'Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS. 2000;14:499-507.
10. Clark RA, Squires KE. Gender-specific considerations in the antiretroviral management of HIV-infected women. Expert Rev Anti Infect Ther. 2005;3:213-227.
11. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391-2400.
12. De Santis M, Carducci B, De Santis L, et al. Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med. 2002;162:355.
13. Smith CJ, Sabin CA, Lampe FC, et al. The relationship between CD4 cell nadirs and the toxicity profiles of antiretroviral regimens. Antivir Ther. 2005;10:459-467.
14. Youle M, Sawyer W, for the HIV Health Economics Collaboration. Reasons for discontinuation of antiretroviral treatment: a clinical survey. AIDS. 1998;12:186.
15. Van Roon EN, Verzijl JM, Juttmann JR. Incidence of discontinuation of highly active antiretroviral therapy (HAART) and its determinants. J Acquir Immune Defic Syndr. 1999;20:290-294.
16. O'Brien ME, Clark RA, Besch CL, et al. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr. 2003;34:407-414.
17. Smith CJ, Phillips AN, Youle MS, et al. Treatment outcomes amongst previously antiretroviral-naïve patients starting Kaletra-containing antiretroviral regimens at the Royal Free Hospital. HIV Med. 2007;8:55-63.
18. Dorrucci M, Pezzotti P, Grisorio B, et al. Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens. AIDS. 2001;15:1733-1736.
19. Sabin CA, for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study. Response to combination antiretroviral therapy (cART): variation by age [abstract 528]. Presented at: 14th Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles.
20. U.S. Food and Drug Administration. Guidance for industry. Antiretroviral drugs using plasma HIV RNA measurements - clinical considerations for accelerated and traditional approval. Available at: http://www.fda.gov/cder/ guidance/index.htm. Accessed July 10, 2007.
21. Kuyper LM, Wood E, Montaner JSG, et al. Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-infected patients in a population-based cohort. J Acquir Immune Defic Syndr. 2004;37:1470-1476.
22. Grabar S, Pradier C, Le Corfec E, et al. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS. 2000;14:141-149.
23. Phillips AN, Staszewski S, Weber R, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA. 2001;286:2560-2567.
24. Descamps D, Flandre P, Calvez V, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. JAMA. 2000;283:205-211.
25. Miller V, Staszewski S, Sabin CA, et al. CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load. J Infect Dis. 1999;180:530-533.
26. Mocroft A, Ruiz L, Reiss P, et al. Virological rebound after suppression on highly active antiretroviral therapy. AIDS. 2003;17:1741-1751.
27. Smith CJ, Phillips AN, Hill T, et al. The rate of viral rebound after attainment of viral load below 50 copies/ml according to specific antiretroviral drugs in use. J Infect Dis. 2005;192:1387-1397.
28. Frater AJ, Dunn DT, Beardall AJ, et al. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS. 2002;16:1139-1146.
29. Le Moing V, Chene G, Carrieri MP, et al. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS. 2002;16:21-29.
30. Smith CJ, Sabin CA, Youle MS, et al. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis. 2004;190:1860-1868.
31. Kaufmann GR, Bloch M, Zaunders JJ, et al. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS. 2000;14:959-969.
32. Connick E, Lederman MM, Kotzin BL, et al. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis. 2000;181:358-363.
33. Moore AL, Kirk O, Johnson AM, et al. Virologic, immunologic and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr. 2003;32:452-461.
34. Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS. 2001;15:1115-1123.
35. Giordano TP, Wright JA, Hasan MQ, et al. Do sex and race/ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy? Clin Infect Dis. 2002;37:433-437.